NeuroPace (NASDAQ:NPCE) versus Autonomix Medical (NASDAQ:AMIX) Head to Head Analysis

NeuroPace (NASDAQ:NPCE) and Autonomix Medical (NASDAQ:AMIX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Earnings & Valuation

This table compares NeuroPace and Autonomix Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99 million	5.64	-$21.47 million	($0.65)	-25.45
Autonomix Medical	N/A	N/A	-$11.41 million	($3.55)	-0.11

Autonomix Medical has lower revenue, but higher earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for NeuroPace and Autonomix Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1	1	4	2	2.88
Autonomix Medical	1	1	1	0	2.00

NeuroPace currently has a consensus target price of $18.83, suggesting a potential upside of 13.87%. Autonomix Medical has a consensus target price of $2.00, suggesting a potential upside of 400.00%. Given Autonomix Medical’s higher possible upside, analysts clearly believe Autonomix Medical is more favorable than NeuroPace.

Profitability

This table compares NeuroPace and Autonomix Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Autonomix Medical	N/A	-239.36%	-192.46%

Institutional & Insider Ownership

78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Comparatively, 6.2% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

NeuroPace has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Autonomix Medical has a beta of -1.82, indicating that its share price is 282% less volatile than the S&P 500.

Summary

NeuroPace beats Autonomix Medical on 10 of the 14 factors compared between the two stocks.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

About Autonomix Medical

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.